The CAR T-Cell therapy landscape shows strong and diverse infrastructures economically, as well as clinically. In this webinar, we explore real-world evidence generation beyond clinical trials, with a focus on economic challenges, outcomes measurements, especially how CAR T-cell data assets can be leveraged to equip life science companies for multi-stakeholder agreements in the future.

3 Key take-aways:

• The latest CAR T-Cell therapy market developments impacting life science companies
• How to best prepare for future economic challenges in CAR T-Cell therapy
• Discover how CAR T-Cell data assets can be leveraged to address future market fluctuations